CN113728103B - 治疗精神分裂症和其他神经精神病症的方法 - Google Patents

治疗精神分裂症和其他神经精神病症的方法 Download PDF

Info

Publication number
CN113728103B
CN113728103B CN201980091600.4A CN201980091600A CN113728103B CN 113728103 B CN113728103 B CN 113728103B CN 201980091600 A CN201980091600 A CN 201980091600A CN 113728103 B CN113728103 B CN 113728103B
Authority
CN
China
Prior art keywords
smad4
glial
scz
cells
entirety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980091600.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113728103A (zh
Inventor
S·A·戈德曼
Z·刘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Priority to CN202510144182.8A priority Critical patent/CN119925614A/zh
Publication of CN113728103A publication Critical patent/CN113728103A/zh
Application granted granted Critical
Publication of CN113728103B publication Critical patent/CN113728103B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
CN201980091600.4A 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法 Active CN113728103B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510144182.8A CN119925614A (zh) 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862778145P 2018-12-11 2018-12-11
US62/778,145 2018-12-11
PCT/US2019/065742 WO2020123663A1 (en) 2018-12-11 2019-12-11 Methods of treating schizophrenia and other neuropsychiatric disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510144182.8A Division CN119925614A (zh) 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法

Publications (2)

Publication Number Publication Date
CN113728103A CN113728103A (zh) 2021-11-30
CN113728103B true CN113728103B (zh) 2025-02-28

Family

ID=69160318

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980091600.4A Active CN113728103B (zh) 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法
CN202510144182.8A Pending CN119925614A (zh) 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510144182.8A Pending CN119925614A (zh) 2018-12-11 2019-12-11 治疗精神分裂症和其他神经精神病症的方法

Country Status (7)

Country Link
US (1) US20220025379A1 (cg-RX-API-DMAC7.html)
EP (1) EP3894556A1 (cg-RX-API-DMAC7.html)
JP (2) JP7518547B2 (cg-RX-API-DMAC7.html)
CN (2) CN113728103B (cg-RX-API-DMAC7.html)
AU (1) AU2019396450B2 (cg-RX-API-DMAC7.html)
CA (1) CA3122289A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020123663A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9709553B2 (en) 2008-05-08 2017-07-18 University Of Rochester Treating myelin diseases with optimized cell preparations
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
CN118924886A (zh) * 2023-03-16 2024-11-12 郑州大学 肿瘤共享新抗原表位肽或其编码核酸的新用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080119427A1 (en) 1996-06-06 2008-05-22 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
BRPI0008131B8 (pt) 1999-02-12 2021-05-25 Daiichi Sankyo Co Ltd composto ou um sal deste, análogo de oligonucleotídeo, composição farmacêutica, sonda para um gene,iniciador para começar a amplificação, uso de um análogo de oligonucleotídeo ou de um sal deste farmacologicamente aceitável, agente antisentido, e, agente antígeno
US6013787A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad4 expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
EP2182063A3 (en) 2003-09-18 2012-07-18 Isis Pharmaceuticals, Inc. Modulation of EIF4E expression
US7128264B2 (en) 2004-07-23 2006-10-31 Symbol Technologies, Inc: Electro-optical reader with improved performance in high intensity ambient light
JP4428296B2 (ja) 2005-06-10 2010-03-10 セイコーエプソン株式会社 表示パネルモジュールおよび表示装置
US9962558B2 (en) * 2005-08-05 2018-05-08 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
EP2315829B1 (en) 2008-08-08 2015-02-11 Mayo Foundation For Medical Education And Research Induced pluripotent stem cells
WO2011062963A2 (en) 2009-11-17 2011-05-26 Vitro Diagnositics, Inc. Induced puripotent stem cells and related methods
US9005967B2 (en) 2010-01-22 2015-04-14 Kyoto University Myc variants improve induced pluripotent stem cell generation efficiency
EP2723861A4 (en) * 2011-06-21 2014-12-10 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR INHIBITING HEPCIDINE ANTIMICROBIAL PEPTIDE (HAMP) OR THE ASSOCIATED GENE EXPRESSION
AU2012332269B2 (en) * 2011-11-04 2018-05-31 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (DA) neurons for engraftment
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US20180263226A1 (en) 2015-01-16 2018-09-20 The Board Of Regents Of The University Of Texas System Compositions and methods for creating pancreatic cancer animal model

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region;Takahiro Mukai等;Frontiers in Pharmacology;第9卷;Article 845,第1-9页 *
Dysregulated Glial Differentiation in Schizophrenia May Be Relieved by Suppression of SMAD4- and REST-Dependent Signaling;Zhengshan Liu等;Cell Reports;20190625;第27卷;3832–3843 *
HDAC2-dependent antipsychotic-like effects of chronic treatment with the HDAC inhibitor SAHA in mice;Mario de la Fuente Revenga等;Neuroscience;第388卷;102–117 *
Ping-Tao Tseng等.Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia.Medicine.2016,第95卷(第4期),1-10. *
Po-Sheng Wang等.The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia.International Clinical Psychopharmacology.2014,第29卷(第4期),235-238. *
Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia;Ping-Tao Tseng等;Medicine;第95卷(第4期);1-10 *
Takahiro Mukai等.Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region.Frontiers in Pharmacology.2018,第9卷Article 845,第1-9页. *
The Contribution of Glial Molecular Pathology to Schizophrenia;Zhengshan Liu;UR RESEARCH;第1-137页 *
The use of psychiatric drugs and worsening body mass index among inpatients with schizophrenia;Po-Sheng Wang等;International Clinical Psychopharmacology;第29卷(第4期);235-238 *

Also Published As

Publication number Publication date
CA3122289A1 (en) 2020-06-18
CN113728103A (zh) 2021-11-30
JP7518547B2 (ja) 2024-07-18
US20220025379A1 (en) 2022-01-27
JP2024129091A (ja) 2024-09-26
WO2020123663A1 (en) 2020-06-18
JP2022511568A (ja) 2022-01-31
EP3894556A1 (en) 2021-10-20
CN119925614A (zh) 2025-05-06
AU2019396450A1 (en) 2021-06-24
AU2019396450B2 (en) 2025-08-28

Similar Documents

Publication Publication Date Title
JP7518547B2 (ja) 統合失調症及び他の神経精神障害の治療方法
KR20190051020A (ko) 안 질환 치료용 안티센스 올리고뉴클레오타이드
JP2021520200A (ja) 非神経細胞のニューロンへの再プログラミング、及び神経変性疾患または障害を治療するための方法と組成物
JP2024075673A (ja) 統合失調症及び他の神経精神障害の治療方法
CN120022289A (zh) 血管生成素样7(angptl7)相关疾病的治疗
KR20260013449A (ko) Mapt를 조절하기 위한 조성물 및 방법
JP7786750B2 (ja) Tcf4遺伝子発現を調節するため、およびピット・ホプキンス症候群を治療するための組成物および方法
WO2021156831A1 (en) Mirna-485 inhibitor for gene upregulation
US20220186228A1 (en) Synthetic microrna mimics
US20260022377A1 (en) Polynucleotide compositions and methods for treatment of neurodegenerative diseases
WO2025049527A1 (en) Y-rna compositions and methods of using the same
HK40130645A (en) Polynucleotide compositions and methods for treatment of neurodegenerative diseases
EP4599061A1 (en) Antisense oligonucleotides for treatment of usher 2a. exon 68

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant